Oncology Nurses on the Frontlines of Immunotherapy Care
Cancer immunotherapies continue to show promising clinical outcomes, notably long-lasting remission, for an increasing number of malignancies.
Frontline Olaparib Plus Abiraterone Provides Consistent Clinical Benefit in HRR-Mutated mCRPC
Assessing Subsequent Therapies in mHSPC Confirms OS Benefit From Darolutamide
Long-term Regorafenib Remission in mCRC May Be Linked to ECOG Score, Less Advanced Disease
Abiraterone Plus Prednisone, Apalutamide Improves Prostate Cancer Outcomes Without Impacting HRQoL
2 Commerce Drive Cranbury, NJ 08512